Ropes & Gray Advises Xilio Therapeutics in Gilead Sciences Exclusive Global License Agreement Up to $647.5M
March 29, 2024
March 29, 2024
BOSTON, Massachusetts, March 29 -- Ropes and Gray, a law firm, issued the following news on March 28, 2024:
Ropes & Gray represented Xilio Therapeutics, Inc., in an exclusive global license agreement with Gilead Sciences to develop and commercialize Xilio's tumor-activated IL-12 program, XTX301. The transaction was announced on March 28.
Xilio Therapeutics is using its proprietary tumor-activation platform to build a pipeline of novel, tumor-activated molecules . . .
Ropes & Gray represented Xilio Therapeutics, Inc., in an exclusive global license agreement with Gilead Sciences to develop and commercialize Xilio's tumor-activated IL-12 program, XTX301. The transaction was announced on March 28.
Xilio Therapeutics is using its proprietary tumor-activation platform to build a pipeline of novel, tumor-activated molecules . . .